Last updated: October 22, 2026
Cardiolite is the branded technetium Tc-99m sestamibi kit marketed by Bracco Diagnostics for myocardial perfusion imaging and selected breast-imaging applications. Its core drug patents and regulatory exclusivity have expired, and the product now competes in a mature market with generic sestamibi kits, hospital-compounded radiopharmaceuticals, PET imaging, and other cardiac SPECT agents. Bracco does not publicly disclose standalone Cardiolite revenue, so the product’s financial trajectory must be assessed through market position, utilization, reimbursement, manufacturing economics, and competitive intensity rather than reported product sales.
What is Cardiolite and how is it used?
Cardiolite contains a lyophilized kit for preparation of technetium Tc-99m sestamibi injection. The kit is not administered as a finished radioactive product. A nuclear pharmacy or authorized radiopharmacy adds sodium pertechnetate Tc-99m to prepare the injectable agent.
The principal FDA-labeled uses are:
- Myocardial perfusion imaging for detection of coronary artery disease.
- Assessment of myocardial perfusion and ventricular function.
- Adjunctive imaging of breast lesions as an alternative to biopsy in limited circumstances, not as a replacement for mammography or definitive diagnosis.
Cardiolite is used in SPECT imaging. Its commercial demand is tied to the number of nuclear cardiology procedures, hospital and outpatient imaging capacity, technetium-99m availability, and reimbursement for SPECT-based diagnostics.
Product and manufacturer profile
| Item |
Detail |
| Brand |
Cardiolite |
| Active imaging agent |
Technetium Tc-99m sestamibi |
| Dosage form |
Kit for preparation of a radiopharmaceutical |
| Principal manufacturer |
Bracco Diagnostics Inc. |
| FDA application |
NDA 19-785 |
| Primary indications |
Myocardial perfusion imaging; selected breast imaging |
| Imaging modality |
SPECT |
| Therapeutic category |
Diagnostic radiopharmaceutical |
| Biosimilar relevance |
None; Cardiolite is a small-molecule diagnostic product |
| Regulatory pathway for competitors |
ANDA or 505(b)(2), depending on product and formulation |
What is the FDA regulatory status of Cardiolite?
Cardiolite is an FDA-approved diagnostic radiopharmaceutical. It is regulated as a drug product and must meet requirements covering chemistry, manufacturing, quality control, radiochemical purity, sterility, labeling, and distribution.
The product’s commercial lifecycle is mature. FDA approval occurred decades ago, and the original regulatory exclusivity period has ended. Cardiolite does not have biologic exclusivity and does not benefit from the 12-year reference-product exclusivity framework applicable to certain biologics.
The product remains commercially relevant because hospitals require reliable access to myocardial perfusion agents, while radiopharmacies value products with established preparation procedures, validated quality specifications, and predictable distribution.
What patents protect Cardiolite?
The principal patent estate for Cardiolite is no longer a meaningful barrier to generic entry. Core composition, use, and product-development patents associated with technetium Tc-99m sestamibi have expired or lost practical exclusivity after decades of commercial use.
The most important protection today is operational rather than patent-based:
- Manufacturing know-how for sterile kit production.
- Quality-control procedures for radiochemical purity.
- Stability data and validated storage conditions.
- Supply agreements with radiopharmacies and health systems.
- Distribution infrastructure for short-lived radioactive isotopes.
- Brand recognition among nuclear medicine departments.
Orange Book status
The FDA Orange Book is the principal source for listed patents and exclusivity associated with approved drug products. Cardiolite’s original patent protection and regulatory exclusivity are expired. The commercial product therefore operates in an environment where approved generic or therapeutically equivalent alternatives can compete.
A patent listing, if present for a specific formulation or approved labeling element, would not recreate the broad market exclusivity that existed during the product’s launch period. The key commercial issue is whether an asserted patent could delay a particular competitor, not whether it could prevent all generic sestamibi supply.
| Protection category |
Current commercial effect |
| Original composition patents |
Expired |
| Original use patents |
Expired or no longer commercially blocking |
| FDA exclusivity |
Expired |
| Formulation protection |
Limited practical value for the mature kit product |
| Manufacturing know-how |
Relevant but difficult to quantify publicly |
| Brand and distribution |
More important than patent rights |
When did Cardiolite lose exclusivity?
Cardiolite lost meaningful market exclusivity many years ago. The product was approved in the early 1990s, and the statutory periods applicable to its original approval have long expired.
The relevant distinction is between legal exclusivity and commercial persistence. Cardiolite no longer has a defensible monopoly based on its original patents, but it can retain sales through:
- Physician familiarity.
- Institutional purchasing contracts.
- Nuclear pharmacy relationships.
- Reliable kit availability.
- Established preparation protocols.
- Regulatory confidence.
- Switching costs at the hospital and radiopharmacy level.
This pattern is typical for mature injectable diagnostics. A branded product may continue to sell after patent expiry when supply reliability and procurement continuity matter more than brand price.
How many patents cover Cardiolite today?
No meaningful blocking patent estate is required to explain Cardiolite’s current market position. The product’s competitive position is based primarily on regulatory approval, manufacturing execution, supply-chain scale, and customer relationships.
Patent-count analysis is therefore less informative than analysis of:
- FDA-approved competing products.
- Manufacturing site capacity.
- Technetium-99m access.
- Radiopharmacy distribution.
- Reimbursement and procedure volume.
- Contract pricing.
No biosimilar pathway applies. Generic competitors do not need to demonstrate biosimilarity because sestamibi is a defined small-molecule diagnostic agent.
Which companies compete with Cardiolite?
Competition comes from generic sestamibi products, other SPECT agents, PET myocardial perfusion agents, and non-nuclear cardiac imaging.
Direct product competition
Generic technetium Tc-99m sestamibi kits are the closest substitutes. Companies active in the broader radiopharmaceutical and nuclear pharmacy market include Jubilant DraxImage, Curium, Cardinal Health, and regional radiopharmacy suppliers. Product availability varies by country, FDA status, manufacturing location, and distribution network.
The direct competitive advantages of a generic kit include lower acquisition cost and formulary substitution. Cardiolite’s advantages are brand familiarity, legacy clinical use, and potentially broader institutional acceptance.
Modality competition
Cardiolite also competes indirectly with:
- Technetium Tc-99m tetrofosmin SPECT products.
- Rubidium-82 PET myocardial perfusion imaging.
- Nitrogen-13 ammonia PET, where available.
- Stress echocardiography.
- Coronary CT angiography.
- Cardiac magnetic resonance imaging.
PET can provide higher image quality and improved attenuation correction in suitable centers, but its adoption is constrained by scanner availability, isotope logistics, reimbursement, and capital requirements. SPECT remains more widely installed, which supports the underlying market for sestamibi.
What market forces affect Cardiolite demand?
Cardiolite demand is linked to the number and type of cardiac imaging procedures rather than to chronic prescription volume. The product is consumed episodically at the point of imaging.
Nuclear cardiology procedure volume
The largest demand driver is myocardial perfusion imaging. Utilization is influenced by:
- Coronary artery disease prevalence.
- Ageing populations.
- Cardiology referral patterns.
- Appropriate-use criteria.
- Alternative imaging adoption.
- Hospital outpatient volumes.
- Payer authorization rules.
Nuclear cardiology has faced utilization pressure from improved clinical triage, changes in testing guidelines, and competition from coronary CT angiography and stress echocardiography. At the same time, established SPECT capacity and continuing coronary disease burden support a large replacement market.
Technetium-99m supply
Technetium-99m is generated from molybdenum-99 through a supply chain that includes reactors, generators, radiopharmacies, and local delivery networks. Short half-life creates high logistical sensitivity. A product with strong demand can still experience revenue volatility if isotope supply interruptions reduce procedure volumes.
Supply reliability has strategic value because hospitals cannot hold large inventories of finished technetium-99m products. The effective market is regional, not purely national.
Reimbursement and hospital economics
Cardiolite revenue is affected by reimbursement for the imaging procedure, not by the kit price alone. Hospitals and outpatient centers evaluate:
- Total reimbursement per scan.
- Radiopharmaceutical acquisition cost.
- Radiologist and technologist labor.
- Generator and radiopharmacy fees.
- Equipment utilization.
- Payer coverage restrictions.
Price competition is strongest where multiple generic kits are available and procurement is centralized.
What is Cardiolite’s financial trajectory?
Cardiolite is best characterized as a mature, cash-generating diagnostic product with limited volume growth and declining price power. Bracco Diagnostics is privately held and does not provide a public, audited Cardiolite revenue series comparable to a public pharmaceutical company’s product-level reporting.
The likely financial profile has four phases:
| Period |
Financial characteristic |
| Launch and adoption |
Rapid growth driven by new use of sestamibi in cardiac SPECT |
| Peak commercial period |
High-value branded sales supported by limited direct competition |
| Patent-expiry period |
Price pressure and generic entry |
| Mature phase |
Stable or declining volume, lower price, recurring institutional demand |
Current revenue depends more on retention than expansion. The product can remain profitable because kit manufacturing and distribution are repeatable, while the underlying clinical workflow remains established. Margin pressure comes from generic competition, hospital purchasing consolidation, reimbursement constraints, and isotope-related supply costs.
Revenue exposure
Cardiolite revenue is exposed to four variables:
- Cardiac SPECT procedure volume.
- Branded-versus-generic market share.
- Net price after institutional discounts.
- Manufacturing and distribution costs.
Bracco’s broader diagnostic portfolio can reduce dependence on any single product. Cardiolite’s standalone contribution is not publicly reported, so precise revenue or EBITDA estimates would be speculative.
What patent litigation and Paragraph IV risk affect Cardiolite?
Cardiolite is not currently defined by an active, high-value Paragraph IV litigation campaign. The relevant patent risk was concentrated during the period when generic manufacturers sought approval and challenged any remaining listed patents.
Because the original patent estate is expired or commercially weak, future generic entry risk is driven less by patent litigation than by:
- FDA approval of competing kits.
- Manufacturing inspection outcomes.
- Product shortages.
- Radiochemical quality issues.
- Distribution access.
- Contracting decisions by hospitals and radiopharmacies.
A Paragraph IV certification could still arise for a newly listed patent tied to a specific formulation or use, but such a patent would need to survive scrutiny and establish a commercially meaningful delay. For a mature sestamibi kit, the probability of broad, durable exclusion from a late patent is low.
What formulation patents protect Cardiolite?
Cardiolite’s formulation is a sterile lyophilized kit that supports preparation of Tc-99m sestamibi before administration. Formulation and manufacturing details can be technically important, but they are not equivalent to broad market exclusivity.
Potentially protectable technical features include:
- Excipient composition.
- Ligand and reducing-agent ratios.
- Lyophilization cycle.
- Stability profile.
- Radiochemical purity.
- Container-closure system.
- Reconstitution conditions.
In practice, generic applicants may design around formulation claims or rely on their own validated manufacturing processes. The commercial barrier is often regulatory validation and sterile manufacturing capability rather than an enforceable formulation patent.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers remain more important than patent barriers. A competitor must produce a sterile, consistent kit and coordinate it with a short-lived radioactive isotope supply chain.
Key barriers include:
- FDA-compliant sterile manufacturing.
- Batch release testing.
- Radiochemical purity controls.
- Reliable access to molybdenum-99 and Tc-99m generators.
- Regional radiopharmacy distribution.
- Product stability and shipping validation.
- Emergency replacement capacity.
- Hospital conversion and training.
These barriers can slow entry but do not create permanent exclusivity. They also create opportunities for companies with existing nuclear medicine infrastructure to gain share quickly when a competitor experiences shortages.
How does Cardiolite compare with competing cardiac imaging agents?
| Factor |
Cardiolite |
Tc-99m tetrofosmin |
Rubidium-82 PET |
Coronary CT angiography |
| Modality |
SPECT |
SPECT |
PET |
CT |
| Supply requirement |
Tc-99m generator or radiopharmacy |
Tc-99m generator or radiopharmacy |
Rubidium generator |
Iodinated contrast |
| Patent risk |
Low |
Generally mature |
Product and generator-specific |
Device and software-driven |
| Infrastructure |
Broad SPECT installed base |
Broad SPECT installed base |
PET-capable centers |
CT-capable centers |
| Main advantage |
Established cardiac workflow |
Alternative SPECT agent |
High-quality perfusion imaging |
Anatomic coronary assessment |
| Main constraint |
Procedure and price pressure |
Same SPECT market pressures |
Cost and availability |
Radiation, contrast, and clinical selection |
Cardiolite’s strongest competitive asset is the installed base of SPECT systems and trained nuclear medicine personnel. Its main weakness is that SPECT is a mature modality with limited pricing power.
What generic launch scenarios exist for Cardiolite?
Three scenarios are commercially relevant.
Scenario 1: Continued branded retention
Bracco retains meaningful share through supply reliability, contracting, and customer familiarity. Revenue declines gradually as generic discounts increase, but the product remains profitable.
Scenario 2: Accelerated generic substitution
Hospitals and radiopharmacies move rapidly to lower-priced sestamibi kits. Cardiolite becomes a secondary or contingency product, with revenue declining faster than procedure volume.
Scenario 3: Supply-driven share reversal
A generic shortage, manufacturing interruption, or isotope disruption shifts demand temporarily back to Cardiolite. This can create short-term revenue increases without changing the long-term mature-product trajectory.
What licensing deals affect Cardiolite?
The product’s historical development and ownership involved legacy pharmaceutical and diagnostic-company transactions. Bracco became the relevant commercial owner after acquiring assets associated with the diagnostic imaging portfolio previously connected with Bristol-Myers Squibb and DuPont.
No current public licensing arrangement is central to Cardiolite’s market outlook. The business is primarily controlled through manufacturing, distribution, regulatory ownership, and customer contracts rather than through a visible third-party royalty structure.
What is the geographic coverage of Cardiolite?
Cardiolite has had broad international use, but its commercial position differs by jurisdiction. Market access depends on:
- Local product registration.
- National reimbursement.
- Nuclear medicine infrastructure.
- Technetium-99m supply.
- Radiopharmacy density.
- Generic approval standards.
- Hospital procurement rules.
The United States remains strategically important because of its large installed SPECT base and established nuclear cardiology market. Europe and other developed markets have stronger national procurement and generic substitution pressures. Emerging markets may have lower procedure volumes but can offer growth where cardiac imaging infrastructure is expanding.
How strong is the Cardiolite patent estate?
The patent estate is weak as a current exclusivity mechanism because the core patents are expired and the product has been exposed to generic competition for years. The overall commercial defense is stronger than the patent estate because of manufacturing know-how, customer relationships, and supply-chain execution.
| Strength factor |
Assessment |
| Core composition patents |
Weak or expired |
| Regulatory exclusivity |
Expired |
| Formulation patents |
Limited blocking potential |
| Brand recognition |
Moderate |
| Manufacturing capability |
Potentially meaningful |
| Distribution |
Meaningful in radiopharmacy markets |
| Switching costs |
Moderate |
| Biosimilar protection |
Not applicable |
| Litigation leverage |
Low |
Key Takeaways
- Cardiolite is a mature Tc-99m sestamibi SPECT product marketed by Bracco Diagnostics.
- Its original patent and regulatory exclusivity have expired.
- No biosimilar framework applies because sestamibi is a small-molecule diagnostic agent.
- Generic sestamibi kits are the main direct competitive threat.
- PET, coronary CT angiography, stress echocardiography, and cardiac MRI pressure long-term SPECT growth.
- Cardiolite revenue is not separately disclosed by Bracco.
- The product’s financial trajectory is likely stable-to-declining, with price pressure exceeding any procedure-volume growth.
- Manufacturing quality, technetium-99m access, and radiopharmacy distribution matter more than patents.
- Paragraph IV risk is secondary to FDA approval, supply reliability, and hospital contracting.
- Cardiolite remains commercially defensible as an established product, but it no longer has a strong patent-based moat.
FAQs
Is Cardiolite still patent protected?
Cardiolite’s core patent protection has expired. Any later patent covering a narrow formulation or use would not recreate the original market exclusivity.
Is Cardiolite interchangeable with generic sestamibi?
Generic technetium Tc-99m sestamibi products are intended to compete directly with Cardiolite, but substitution depends on FDA therapeutic-equivalence status, institutional policy, contracting, and product availability.
Does Cardiolite have biosimilar competition?
No. Biosimilars apply to biologic products. Cardiolite contains the small molecule sestamibi in a radiopharmaceutical kit.
What is the largest financial risk to Cardiolite?
The largest risk is sustained generic price erosion combined with declining or flat SPECT procedure volume. Short-lived isotope supply interruptions can create temporary volatility.
Can PET replace Cardiolite?
PET can replace SPECT in centers with appropriate scanners, isotopes, reimbursement, and clinical capacity. It is unlikely to eliminate Cardiolite demand across the broader market because SPECT infrastructure is more widely distributed.
References
-
Bracco Diagnostics Inc. (n.d.). Cardiolite prescribing information. Bracco Diagnostics.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Centers for Medicare & Medicaid Services. (n.d.). Medicare physician fee schedule and outpatient payment resources. https://www.cms.gov/medicare/payment
-
National Academies of Sciences, Engineering, and Medicine. (2022). Molybdenum-99 for medical imaging. National Academies Press.
-
International Atomic Energy Agency. (n.d.). Molybdenum-99 and technetium-99m supply. https://www.iaea.org/topics/molybdenum-99-technetium-99m
-
U.S. Food and Drug Administration. (n.d.). Generic drugs and abbreviated new drug applications. https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs-facts-consumers
